< Back to latest news & events

Event

Life Sciences Patent Network Europe 2019

November 2019

Event date: 21st November 2019

HGF Partner Dr Claire Irvine will be hosting a roundtable on Navigating the CRISPR patent and licensing landscape at Life Sciences Patent Network Europe 2019 on 21st November.

CRISPR gene-editing continues to hit the headlines regularly as a ground-breaking technology with many millions now flowing into companies seeking to exploit the technology in both the therapeutic and agricultural fields. Unfortunately, the IP landscape continues to lack clarity with possibility of divergence between Europe and the US.

Oral proceedings for the University of California have been scheduled at the EPO for early February 2020 with the preliminary non-binding opinion of the opposition division favouring the patentees on coverage extending to CRISPR/Cas9 gene-editing in eukaryotic cells.

Join Dr Claire Irvine’s roundtable session, where she will discuss and update you on:

  • The CRISPR IP saga and the interplay between the latest chapter in Europe and the US
  • New interference proceedings instigated by the USPTO
  • Opposition and appeal proceedings affecting key European patents at the European Patent Office
  • The considerations about freedom-to-operate in the absence of resolution of a standard for CRISPR gene-editing for therapy and the growing number of claims outside the main battle lines.

Latest updates

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The Enlarged Board of Appeal has today issued its decision in seminal case G1/24

G1/24, described as one of the most important cases in decades, relates to how claims of patents are to be interpreted by the Boards of Appeal and, by extension, all …

Read article

UPC’s Hamburg Local Division provides guidance on the extent to which a patent may be used as its own “lexicon”

Agfa NV v Gucci & Anors. [UPC_CFI_278/2023] – Hamburg Local Division of the UPC (Klepsch, Schilling, Sarlin) – 30 April 2025 While we await a decision on G1/24 from the …

Read article

MevoCem Nominated for the Earthshot Prize by CIPA

We’re delighted to share that our client, Material Evolution, has been nominated by the Chartered Institute of Patent Attorneys (CIPA) for the globally renowned Earthshot Prize, in recognition of their …

Read article

Agritech Thymes: Agritech 2030: Forecasting the Technologies Poised to Transform Farming

Whilst yet to recover to the levels of 2011-2021, where capital invested in agritech increased 20-fold, investor funding in agritech is starting to pick up, and 2025 is set to …

Read article

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

Sanofi Biotechnology SAS & Anor v Amgen, Inc., & Ors– Thomas, Thom, Kupecz and Dorland-Galliot – [UPC_CFI_505/2024] The Dusseldorf Local Division (LD) has delivered the UPC’s first Judgment on second …

Read article